146 related articles for article (PubMed ID: 35347559)
1. Phase I Study of Glesatinib (MGCD265) in Combination with Erlotinib or Docetaxel in Patients with Advanced Solid Tumors.
Patnaik A; Gadgeel S; Papadopoulos KP; Rasco DW; Haas NB; Der-Torossian H; Faltaos D; Potvin D; Tassell V; Tawashi M; Chao R; O'Dwyer PJ
Target Oncol; 2022 Mar; 17(2):125-138. PubMed ID: 35347559
[TBL] [Abstract][Full Text] [Related]
2. Phase I Study Evaluating Glesatinib (MGCD265), An Inhibitor of MET and AXL, in Patients with Non-small Cell Lung Cancer and Other Advanced Solid Tumors.
Kollmannsberger C; Hurwitz H; Bazhenova L; Cho BC; Hong D; Park K; Reckamp KL; Sharma S; Der-Torossian H; Christensen JG; Faltaos D; Potvin D; Tassell V; Chao R; Shapiro GI
Target Oncol; 2023 Jan; 18(1):105-118. PubMed ID: 36459255
[TBL] [Abstract][Full Text] [Related]
3. A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumors.
Infante JR; Cohen RB; Kim KB; Burris HA; Curt G; Emeribe U; Clemett D; Tomkinson HK; LoRusso PM
Invest New Drugs; 2017 Oct; 35(5):576-588. PubMed ID: 28424891
[TBL] [Abstract][Full Text] [Related]
4. A phase I dose-escalation study of selumetinib in combination with docetaxel or dacarbazine in patients with advanced solid tumors.
LoRusso PM; Infante JR; Kim KB; Burris HA; Curt G; Emeribe U; Clemett D; Tomkinson HK; Cohen RB
BMC Cancer; 2017 Mar; 17(1):173. PubMed ID: 28264648
[TBL] [Abstract][Full Text] [Related]
5. A Phase Ib multicenter, dose-escalation study of the polyamine analogue PG-11047 in combination with gemcitabine, docetaxel, bevacizumab, erlotinib, cisplatin, 5-fluorouracil, or sunitinib in patients with advanced solid tumors or lymphoma.
Murray Stewart T; Von Hoff D; Fitzgerald M; Marton LJ; Becerra CHR; Boyd TE; Conkling PR; Garbo LE; Jotte RM; Richards DA; Smith DA; Stephenson JJ; Vogelzang NJ; Wu HH; Casero RA
Cancer Chemother Pharmacol; 2021 Jan; 87(1):135-144. PubMed ID: 33215270
[TBL] [Abstract][Full Text] [Related]
6. Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with erlotinib in patients with advanced solid tumors.
Tolcher AW; LoRusso P; Arzt J; Busman TA; Lian G; Rudersdorf NS; Vanderwal CA; Kirschbrown W; Holen KD; Rosen LS
Cancer Chemother Pharmacol; 2015 Nov; 76(5):1025-32. PubMed ID: 26420235
[TBL] [Abstract][Full Text] [Related]
7. Phase I Dose-Escalation Study of Linsitinib (OSI-906) and Erlotinib in Patients with Advanced Solid Tumors.
Macaulay VM; Middleton MR; Eckhardt SG; Rudin CM; Juergens RA; Gedrich R; Gogov S; McCarthy S; Poondru S; Stephens AW; Gadgeel SM
Clin Cancer Res; 2016 Jun; 22(12):2897-907. PubMed ID: 26831715
[TBL] [Abstract][Full Text] [Related]
8. A Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of Pictilisib in Combination with Erlotinib in Patients with Advanced Solid Tumors.
Leong S; Moss RA; Bowles DW; Ware JA; Zhou J; Spoerke JM; Lackner MR; Shankar G; Schutzman JL; van der Noll R; Voest EE; Schellens JHM
Oncologist; 2017 Dec; 22(12):1491-1499. PubMed ID: 28798270
[TBL] [Abstract][Full Text] [Related]
9. Intercalated erlotinib-docetaxel dosing schedules designed to achieve pharmacodynamic separation: results of a phase I/II trial.
Sangha R; Davies AM; Lara PN; Mack PC; Beckett LA; Hesketh PJ; Lau D; Li T; Perkins N; Gandara DR
J Thorac Oncol; 2011 Dec; 6(12):2112-9. PubMed ID: 21892109
[TBL] [Abstract][Full Text] [Related]
10. Phase I Study of Docetaxel and Temsirolimus in Refractory Solid Tumors.
Amin M; Gao F; Terrero G; Picus J; Wang-Gillam A; Suresh R; Ma C; Tan B; Baggstrom M; Naughton MJ; Trull L; Belanger S; Fracasso PM; Lockhart AC
Am J Clin Oncol; 2021 Sep; 44(9):443-448. PubMed ID: 34310349
[TBL] [Abstract][Full Text] [Related]
11. A phase I study of the farnesyltransferase inhibitor Tipifarnib in combination with the epidermal growth factor tyrosine kinase inhibitor Erlotinib in patients with advanced solid tumors.
Jazieh K; Molina J; Allred J; Yin J; Reid J; Goetz M; Lim VS; Kaufmann SH; Adjei A
Invest New Drugs; 2019 Apr; 37(2):307-314. PubMed ID: 30171497
[TBL] [Abstract][Full Text] [Related]
12. Phase I/II study of intermitted erlotinib in combination with docetaxel in patients with recurrent non-small cell lung cancer (WJOG4708L).
Kimura T; Kawaguchi T; Chiba Y; Yoshioka H; Watanabe K; Kijima T; Kogure Y; Oguri T; Yoshimura N; Niwa T; Kasai T; Hayashi H; Ono A; Asai K; Tanaka H; Yano S; Yamamoto N; Nakanishi Y; Nakagawa K
Jpn J Clin Oncol; 2019 Oct; 49(10):947-955. PubMed ID: 31242302
[TBL] [Abstract][Full Text] [Related]
13. Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study.
Lakhani NJ; Chow LQM; Gainor JF; LoRusso P; Lee KW; Chung HC; Lee J; Bang YJ; Hodi FS; Kim WS; Santana-Davila R; Fanning P; Squifflet P; Jin F; Kuo TC; Wan HI; Pons J; Randolph SS; Messersmith WA
Lancet Oncol; 2021 Dec; 22(12):1740-1751. PubMed ID: 34793719
[TBL] [Abstract][Full Text] [Related]
14. Phase I dose-escalation trial of afatinib, an irreversible ErbB family blocker, in combination with gemcitabine or docetaxel in patients with relapsed or refractory solid tumors.
Hiret S; Isambert N; Gomez-Roca C; Bennouna J; Sassi M; de Mont-Serrat H; Fan J; Schnell D; Delord JP
Invest New Drugs; 2018 Dec; 36(6):1044-1059. PubMed ID: 29808308
[TBL] [Abstract][Full Text] [Related]
15. A phase Ib dose-escalation study of erlotinib, capecitabine and oxaliplatin in metastatic colorectal cancer patients.
Van Cutsem E; Verslype C; Beale P; Clarke S; Bugat R; Rakhit A; Fettner SH; Brennscheidt U; Feyereislova A; Delord JP
Ann Oncol; 2008 Feb; 19(2):332-9. PubMed ID: 17986625
[TBL] [Abstract][Full Text] [Related]
16. Phase II study investigating the efficacy and safety of glesatinib (MGCD265) in patients with advanced NSCLC containing MET activating alterations.
Hong DS; Cappuzzo F; Chul Cho B; Dowlati A; Hussein M; Kim DW; Percent I; Christensen JG; Morin J; Potvin D; Faltaos D; Tassell V; Der-Torossian H; Chao R
Lung Cancer; 2024 Apr; 190():107512. PubMed ID: 38417277
[TBL] [Abstract][Full Text] [Related]
17. Phase I Results from a Study of Crizotinib in Combination with Erlotinib in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer.
Ou SI; Govindan R; Eaton KD; Otterson GA; Gutierrez ME; Mita AC; Argiris A; Brega NM; Usari T; Tan W; Ho SN; Robert F
J Thorac Oncol; 2017 Jan; 12(1):145-151. PubMed ID: 27697581
[TBL] [Abstract][Full Text] [Related]
18. Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors.
Molife LR; Yan L; Vitfell-Rasmussen J; Zernhelt AM; Sullivan DM; Cassier PA; Chen E; Biondo A; Tetteh E; Siu LL; Patnaik A; Papadopoulos KP; de Bono JS; Tolcher AW; Minton S
J Hematol Oncol; 2014 Jan; 7():1. PubMed ID: 24387695
[TBL] [Abstract][Full Text] [Related]
19. Safety and pharmacokinetics of motesanib in combination with gemcitabine and erlotinib for the treatment of solid tumors: a phase 1b study.
Kotasek D; Tebbutt N; Desai J; Welch S; Siu LL; McCoy S; Sun YN; Johnson J; Adewoye AH; Price T
BMC Cancer; 2011 Jul; 11():313. PubMed ID: 21791058
[TBL] [Abstract][Full Text] [Related]
20. A phase Ib trial of LY2584702 tosylate, a p70 S6 inhibitor, in combination with erlotinib or everolimus in patients with solid tumours.
Hollebecque A; Houédé N; Cohen EE; Massard C; Italiano A; Westwood P; Bumgardner W; Miller J; Brail LH; Benhadji KA; Soria JC
Eur J Cancer; 2014 Mar; 50(5):876-84. PubMed ID: 24456794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
